Forty Seven (NASDAQ:FTSV)‘s stock had its “buy” rating restated by Oppenheimer in a research report issued to clients and investors on Tuesday.

Several other equities analysts also recently weighed in on FTSV. HC Wainwright initiated coverage on Forty Seven in a research report on Friday, November 30th. They issued a “buy” rating and a $21.00 target price for the company. ValuEngine downgraded Forty Seven from a “buy” rating to a “hold” rating in a research report on Monday, December 17th. BTIG Research initiated coverage on Forty Seven in a research report on Friday, December 21st. They issued a “buy” rating and a $36.00 target price for the company. Zacks Investment Research downgraded Forty Seven from a “hold” rating to a “sell” rating in a research report on Tuesday, January 15th. Finally, FIG Partners initiated coverage on Forty Seven in a research report on Friday, February 1st. They issued a “buy” rating and a $30.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Forty Seven presently has an average rating of “Buy” and a consensus price target of $27.71.

NASDAQ FTSV opened at $18.21 on Tuesday. Forty Seven has a 1-year low of $12.02 and a 1-year high of $23.83.

In other news, Director Ravindra Majeti sold 35,000 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $17.83, for a total transaction of $624,050.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Irving Weissman sold 10,000 shares of the business’s stock in a transaction dated Wednesday, January 9th. The stock was sold at an average price of $17.05, for a total value of $170,500.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 193,247 shares of company stock valued at $3,087,073.

Institutional investors have recently made changes to their positions in the company. Essex Investment Management Co. LLC acquired a new position in shares of Forty Seven during the fourth quarter worth about $70,000. New York State Common Retirement Fund acquired a new position in shares of Forty Seven during the fourth quarter worth about $101,000. Bank of America Corp DE grew its position in shares of Forty Seven by 177.3% during the fourth quarter. Bank of America Corp DE now owns 9,757 shares of the company’s stock worth $153,000 after buying an additional 6,239 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Forty Seven during the fourth quarter worth about $158,000. Finally, Teachers Advisors LLC purchased a new stake in Forty Seven during the third quarter worth approximately $157,000. 43.83% of the stock is owned by institutional investors and hedge funds.

About Forty Seven

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors.

Recommended Story: Momentum Investing

Analyst Recommendations for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.